Biosimilars: part 2: potential concerns and challenges for p&t committees.
P&T committee members need a lot more information before they can evaluate the efficacy and safety, interchangeability, and cost-effectiveness of biosimilar products for inclusion on formularies.
C Lee
CL
Ventola